Nanoparticle-enhanced generation of gene-transfected mesenchymal stem cells for in vivo cardiac repair

Biomaterials

Volumn 74, Issue , 2016, Pages 188-199

  Zhu, Kai ^a,b   Wu, Meiying ^c   Lai, Hao ^a,b   Guo, Changfa ^a,b   Li, Jun ^a,b   Wang, Yulin ^a,b   Chen, Yu ^c   Wang, Chunsheng ^a,b   Shi, Jianlin ^c  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Institute of Cardiovascular Diseases   (China)

^c SHANGHAI INSTITUTE OF CERAMICS   (China)

Author keywords

Cardiac repair; Gene transfection; Large mesopore; Mesoporous organosilica; Stem cell therapy

Indexed keywords

BIOCOMPATIBILITY; CELL CULTURE; CELLS; CYTOLOGY; GENE TRANSFER; GENES; HEART; MOLECULAR BIOLOGY; NANOPARTICLES; PORE SIZE; REPAIR; SILICA; STEM CELLS; SYNTHESIS (CHEMICAL);

CARDIAC REPAIR; GENE TRANSFECTION; LARGE MESOPORE; MESOPOROUS ORGANOSILICAS; STEM CELL THERAPY;

GENE THERAPY;

HOLLOW MESOPOROUS ORGANOSILICA NANOPARTICLE; NANOPARTICLE; SCATTER FACTOR; UNCLASSIFIED DRUG; BIOMATERIAL;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCOMPATIBILITY; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CONTROLLED STUDY; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; IN VIVO STUDY; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RAT; REGENERATIVE MEDICINE; GENETIC TRANSFECTION; GENETICS; HEART; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY;

BIOCOMPATIBLE MATERIALS; HEART; HEPATOCYTE GROWTH FACTOR; MESENCHYMAL STROMAL CELLS; NANOPARTICLES; TRANSFECTION;

EID: 84945161551     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.10.010     Document Type: Article

References (40)

1. Segers V.F.M., Lee R.T. Stem-cell therapy for cardiac disease. Nature 2008, 451:937-942.
2. Williams A.R., Hare J.M. Mesenchymal stem cells biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ. Res. 2011, 109:923-940.
3. Duran J.M., Makarewich C.A., Sharp T.E., Starosta T., Zhu F., Hoffman N.E., et al. Bone-derived stem cells repair the heart after myocardial infarction through transdifferentiation and paracrine signaling mechanisms. Circ. Res. 2013, 113:539-552.
4. Ranganath S.H., Levy O., Inamdar M.S., Karp J.M. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 2012, 10:244-258.
5. Ankrum J.A., Ong J.F., Karp J.M. Mesenchymal stem cells: immune evasive, not immune privileged. Nat. Biotechnol. 2014, 32:252-260.
6. Marbán E., Malliaras K. Mixed results for bone marrow-derived cell therapy for ischemic heart disease. JAMA 2012, 308:2405-2406.
7. Hare J.M., Fishman J.E., Gerstenblith G., Velazquez D.L.D., Zambrano J.P., Suncion V.Y., et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012, 308:2369-2379.
8. Penn M.S., Mangi A.A. Genetic enhancement of stem cell engraftment, survival, and efficacy. Circ. Res. 2008, 102:1471-1482.
9. Deuse T., Peter C., Fedak P.W., Doyle T., Reichenspurner H., Zimmermann W.H., et al. Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation 2009, 120:S247-S254.
10. Tang J., Wang J., Yang J., Kong X., Zheng F., Guo L., et al. Mesenchymal stem cells over-expressing SDF-1 promote angiogenesis and improve heart function in experimental myocardial infarction in rats. Eur. J. Cardio-Thorac. Surg. 2009, 36:644-650.
11. Hodgkinson C.P., Gomez J.A., Mirotsou M., Dzau V.J. Genetic engineering of mesenchymal stem cells and its application in human disease therapy. Hum. Gene Ther. 2010, 21:1513-1526.
12. Bordignon C. Stem-cell therapies for blood diseases. Nature 2006, 441:1100-1102.
13. Walther W., Stein U. Viral vectors for gene transfer - a review of their use in the treatment of human diseases. Drugs 2000, 60:249-271.
14. De Laporte L., Rea J.C., Shea L.D. Design of modular non-viral gene therapy vectors. Biomaterials 2006, 27:947-954.
15. Cui Z.K., Fan J., Kim S., Bezouglaia O., Fartash A., Wu B.M., et al. Delivery of siRNA via cationic sterosomes to enhance osteogenic differentiation of mesenchymal stem cells. J. Control. Release 2015, 217:42-52.
16. Beloor J., Ramakrishna S., Nam K., Seon Choi C., Kim J., Kim S.H., et al. Effective gene delivery into human stem cells with a cell-targeting peptide-modified bioreducible polymer. Small 2015, 11:2069-2079.
17. Gandra N., Wang D.D., Zhu Y., Mao C. Virus-mimetic cytoplasm-cleavable magnetic/silica nanoclusters for enhanced gene delivery to mesenchymal stem cells. Angew. Chem. Int. Ed. 2013, 125:11488-11491.
18. Muroski M.E., Morgan T.J., Levenson C.W., Strouse G.F. A gold nanoparticle pentapeptide: gene fusion to induce therapeutic gene expression in mesenchymal stem cells. J. Am. Chem. Soc. 2014, 136:14763-14771.
19. Chen Y., Chen H., Shi J. In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles. Adv. Mater. 2013, 25:3144-3176.
20. Lee J.E., Lee N., Kim H., Kim J., Choi S.H., Kim J.H., et al. Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery. J. Am. Chem. Soc. 2010, 132:552-557.
21. Lee J.E., Lee N., Kim T., Kim J., Hyeon T. Multifunctional mesoporous silica nanocomposite nanoparticles for theranostic applications. Acc. Chem. Res. 2011, 44:893-902.
22. Vallet-Regi M., Balas F., Arcos D. Mesoporous materials for drug delivery. Angew. Chem. Int. Ed. 2007, 46:7548-7558.
23. Li Z.X., Barnes J.C., Bosoy A., Stoddart J.F., Zink J.I. Mesoporous silica nanoparticles in biomedical applications. Chem. Soc. Rev. 2012, 41:2590-2605.
24. Yang P.P., Gai S.L., Lin J. Functionalized mesoporous silica materials for controlled drug delivery. Chem. Soc. Rev. 2012, 41:3679-3698.
25. Meng H.A., Liong M., Xia T.A., Li Z.X., Ji Z.X., Zink J.I., et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010, 4:4539-4550.
26. Chen A.M., Zhang M., Wei D.G., Stueber D., Taratula O., Minko T., et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009, 5:2673-2677.
27. Chen Y., Chen H.R., Guo L.M., He Q.J., Chen F., Zhou J., et al. Hollow/rattle-type mesoporous nanostructures by a structural difference-based selective etching strategy. ACS Nano 2010, 4:529-539.
28. Chen D., Li L.L., Tang F.Q., Qi S.O. Facile and scalable synthesis of tailored silica "nanorattle" structures. Adv. Mater. 2009, 21:3804-3807.
29. Chen Y., Meng Q., Wu M., Wang S., Xu P., Chen H., et al. Hollow mesoporous organosilica nanoparticles: a generic intelligent framework-hybridization approach for biomedicine. J. Am. Chem. Soc. 2014, 136:16326-16334.
30. Chen Y., Xu P.F., Chen H.R., Li Y.S., Bu W.B., Shu Z., et al. Colloidal HPMO nanoparticles: silica-etching chemistry tailoring, topological transformation, and nano-biomedical applications. Adv. Mater. 2013, 25:3100-3105.
31. Xi B., Yu N., Wang X., Xu X., Abassi Y.A. The application of cell-based label-free technology in drug discovery. Biotechnol. J. 2008, 3(4):484-495.
32. Henry T.D., Hirsch A.T., Goldman J., Wang Y.L., Lips D.L., McMillan W.D., et al. Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase I study. Gene Ther. 2011, 18:788-794.
33. Kim J.S., Hwang H.Y., Cho K.R., Park E.A., Lee W., Paeng J.C., et al. Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: phase I clinical study. Gene Ther. 2013, 20:717-722.
34. Ajroud-Driss S., Christiansen M., Allen J.A., Kessler J.A. Phase 1/2 open-label dose-escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy. Mol. Ther. 2013, 21:1279-1286.
35. Urata C., Yamada H., Wakabayashi R., Aoyama Y., Hirosawa S., Arai S., et al. Aqueous colloidal mesoporous nanoparticles with ethenylene-bridged silsesquioxane frameworks. J. Am. Chem. Soc. 2011, 133:8102-8105.
36. Croissant J., Cattoen X., Man M.W.C., Gallud A., Raehm L., Trens P., et al. Biodegradable ethylene-bis(propyl)disulfide-based periodic mesoporous organosilica nanorods and nanospheres for efficient in-vitro drug delivery. Adv. Mater. 2014, 26:6174-6180.
37. Pack D.W., Hoffman A.S., Pun S., Stayton P.S. Design and development of polymers for gene delivery. Nat. Rev. Drug Discov. 2005, 4:581-593.
38. Ye L., Zhang W., Su L.P., Haider H.K., Poh K.K., Galupo M.J., et al. Nanoparticle based delivery of hypoxia-regulated VEGF transgene system combined with myoblast engraftment for myocardial repair. Biomaterials 2011, 32:2424-2431.
39. Ducharme A., Frantz S., Aikawa M., Rabkin E., Lindsey M., Rohde L.E., et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Invest. 2000, 106:55-62.
40. Purcell B.P., Lobb D., Charati M.B., Dorsey S.M., Wade R.J., Zellars K.N., et al. Injectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibition. Nat. Mater. 2014, 13:653-661.